Skip to main
IFRX

InflaRx (IFRX) Stock Forecast & Price Target

InflaRx (IFRX) Analyst Ratings

Based on 5 analyst ratings
Buy
Strong Buy 60%
Buy 20%
Hold 20%
Sell 0%
Strong Sell 0%

Bulls say

InflaRx is poised for success due to their innovative approach in developing and commercializing inhibitors of the complement activation factor C5a, with promising therapeutic product candidates such as vilobelimab and izicopan. The recent shift in their pipeline to focus on AAV and other inflammatory renal diseases provides multiple opportunities for success, especially with current treatment options being limited. Additionally, the company's strong financial position and plans for rapid proof of concept studies in these indications make them a solid investment choice.

Bears say

InflaRx is facing numerous challenges, including a highly competitive market for its product candidates, especially in the areas of autoimmune and inflammatory diseases. Furthermore, the company's lead asset, izicopan, has shown low reactivemetabolite formation compared to its competitor Tavneos, which may impact its effectiveness in clinical trials. Additionally, the use of corticosteroids in the treatment regimen may confound the efficacy analysis of its experimental drug. This combination of factors leads to a negative outlook for InflaRx's stock, as it may struggle to compete and demonstrate strong clinical efficacy in a crowded market.

InflaRx (IFRX) has been analyzed by 5 analysts, with a consensus rating of Buy. 60% of analysts recommend a Strong Buy, 20% recommend Buy, 20% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of InflaRx and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About InflaRx (IFRX) Forecast

Analysts have given InflaRx (IFRX) a Buy based on their latest research and market trends.

According to 5 analysts, InflaRx (IFRX) has a Buy consensus rating as of Aug 14, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $7.80, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $7.80, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

InflaRx (IFRX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.